476060 — Onconic Therapeutics Balance Sheet
0.000.00%
- KR₩235bn
- KR₩191bn
- KR₩15bn
Annual balance sheet for Onconic Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash | ||||
Cash and Equivalents | ||||
Cash and Short Term Investments | 18,861 | 27,316 | 30,100 | 43,000 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 177 | 847 | 466 | 8,189 |
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 19,048 | 28,171 | 30,759 | 52,134 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 264 | 2,619 | 3,568 | 3,285 |
Net Intangible Assets | ||||
Long Term Notes Receivable | ||||
Other Long Term Assets | ||||
Total Assets | 19,427 | 30,907 | 37,548 | 60,913 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 528 | 26,590 | 57,009 | 4,765 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Funded Status | ||||
Total Liabilities | 27,405 | 52,844 | 57,237 | 4,895 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
ESOP Debt Guarantee | ||||
Other Equity | ||||
Total Equity | -7,978 | -21,937 | -19,690 | 56,019 |
Total Liabilities & Shareholders' Equity | 19,427 | 30,907 | 37,548 | 60,913 |
Total Common Shares Outstanding |